Genzyme Corporation (GENZ) Announces Return to Full Supply of Thyrogen (thyrotropin alfa for injection)  
11/13/2012 10:06:45 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that due to the continued progress in its manufacturing operations this year, its supply of Thyrogen® (thyrotropin alfa for injection) has been fully restored. As a result, beginning in November, Genzyme is able to supply all patient demand globally. “We are grateful to the Thyroid cancer treatment community for its ongoing patience and partnership,” said Genzyme’s Vice President and General Manager of Endocrinology, Alicia Secor. “Genzyme continues to invest in our manufacturing capabilities and we are dedicated to delivering high quality product and continuous supply of Thyrogen for the long term.”